How should supraventricular tachycardia (SVT) be treated acutely and for long‑term management?

Treatment of Supraventricular Tachycardia (SVT)

Begin with vagal maneuvers in stable patients, followed immediately by adenosine if unsuccessful; unstable patients require immediate synchronized cardioversion without delay. 1

Acute Management Algorithm

Step 1: Assess Hemodynamic Stability

Unstable patients (hypotension, altered mental status, shock, chest pain, acute heart failure) require immediate synchronized cardioversion starting at 50–100 J, which restores sinus rhythm in essentially all patients while avoiding drug-related complications. 1 Do not delay cardioversion to attempt pharmacologic conversion in unstable patients. 1

Stable patients proceed through the following stepwise approach:

Step 2: Vagal Maneuvers (First-Line for Stable Patients)

• Modified Valsalva maneuver is the most effective vagal technique, achieving conversion in approximately 43% of cases. 1 The patient should be supine, bearing down against a closed glottis for 10–30 seconds, generating approximately 30–40 mm Hg intrathoracic pressure. 2

• Carotid sinus massage (after confirming absence of carotid bruit by auscultation) involves applying steady pressure over the right or left carotid sinus for 5–10 seconds. 2, 1

• Diving reflex using an ice-cold wet towel applied to the face is an alternative vagal technique. 2, 1

• Never apply pressure to the eyeballs—this practice is contraindicated and potentially dangerous. 2, 1

Step 3: Adenosine (Second-Line Pharmacologic Therapy)

Adenosine is the drug of choice after failed vagal maneuvers, converting 90–95% of AVNRT/AVRT episodes. 2, 1

Dosing protocol:

• 6 mg rapid IV push followed immediately by a 20 mL saline flush 1
• If no conversion within 1–2 minutes, give 12 mg rapid IV push 1

Critical safety requirement: A defibrillator must be immediately available at bedside because adenosine can precipitate atrial fibrillation that may rapidly conduct to ventricular fibrillation. 1

Dose adjustments:

• Reduce initial dose to 3 mg in patients taking dipyridamole or carbamazepine, or in heart transplant recipients 1
• Increase dose when patients are taking theophylline or caffeine 1
• Contraindicated in asthma patients 1

Transient side effects (flushing, chest discomfort, dyspnea) occur in approximately 30% of patients but resolve within less than 1 minute. 1

Step 4: IV Calcium-Channel Blockers or Beta-Blockers (Third-Line)

IV diltiazem or verapamil achieve conversion in 64–98% of cases and are preferred when adenosine fails or beta-blockers are not tolerated. 2, 1

• Infusion over up to 20 minutes can reduce the risk of hypotension 1

Critical contraindications for calcium-channel blockers:

• Do NOT use if ventricular tachycardia or pre-excited atrial fibrillation is possible—these patients may become hemodynamically unstable and develop ventricular fibrillation 2, 1
• Avoid in systolic heart failure 2, 1

IV beta-blockers are reasonable alternatives with an excellent safety profile, though slightly less effective than calcium-channel blockers. 2, 1 Evidence for beta-blocker effectiveness in terminating AVNRT is limited, but their safety profile makes them reasonable to attempt in hemodynamically stable patients. 2

Step 5: Synchronized Cardioversion (Fourth-Line for Stable Patients)

When pharmacologic therapy fails or is contraindicated in stable patients, synchronized cardioversion (after adequate sedation) yields 80–98% success. 2, 1

Special Situation: Pre-Excited Atrial Fibrillation (Wolff-Parkinson-White)

• Unstable pre-excited AF requires immediate synchronized cardioversion 1

• Stable pre-excited AF should be treated with ibutilide or IV procainamide 1

• AV-nodal blocking agents (adenosine, diltiazem, verapamil, digoxin) are absolutely contraindicated because they can enhance accessory-pathway conduction and precipitate ventricular fibrillation 1

Long-Term Management

Catheter Ablation (First-Line for Recurrent SVT)

Catheter ablation is recommended as first-line therapy for recurrent symptomatic SVT, with single-procedure success rates of 94.3–98.5%. 1, 3 This represents a major shift in the 2019 ESC guidelines, which significantly upgraded catheter ablation to preferential status. 2, 4, 5

• Ablation is safe, highly effective, and has a very low complication rate 5
• All patients treated for SVT should be referred for a heart rhythm specialist opinion 6

Long-Term Pharmacotherapy (When Ablation Not Performed)

Oral beta-blockers, diltiazem, or verapamil are effective for ongoing SVT control when ablation is declined or not feasible. 2, 1

• Both diltiazem and verapamil are well-tolerated alternatives to ablation 1
• Patients should be monitored for bradyarrhythmias and hypotension after initiation 1
• These agents should be avoided in systolic heart failure 1

Important downgrade: Most antiarrhythmic drugs previously used for SVT have been downgraded in recent guidelines based on current evidence, with the exception of beta-blockers and calcium-channel blockers. 2, 5 Amiodarone and digoxin are no longer recommended for acute narrow-complex SVT management. 1

Common Pitfalls & Safety Checks

• Never delay cardioversion in unstable patients to attempt pharmacologic conversion 1

• Always have a defibrillator ready when administering adenosine due to the risk of precipitating dangerous atrial fibrillation 1

• Avoid calcium-channel blockers or beta-blockers if there is any suspicion of pre-excited atrial fibrillation or ventricular tachycardia—these patients can develop ventricular fibrillation 2, 1

• Post-conversion premature ventricular complexes can re-initiate SVT; consider anti-arrhythmic therapy to prevent immediate recurrence 1

• Untreated SVT can result in tachycardia-mediated cardiomyopathy (occurring in approximately 1% of patients), heart failure, pulmonary edema, and myocardial ischemia secondary to increased heart rate 2, 3